# Penetration of Moxifloxacin Into Liver Tissue of Patients Undergoing Liver Resection.

> **NCT01302951** · PHASE4 · COMPLETED · sponsor: **University Hospital, Saarland** · enrollment: 34 (actual)

## Conditions studied

- Side-effect of Antibiotic

## Interventions

- **DRUG:** Moxifloxacin 400 mg

## Key facts

- **NCT ID:** NCT01302951
- **Lead sponsor:** University Hospital, Saarland
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-07
- **Primary completion:** 2010-07
- **Final completion:** 2010-07
- **Target enrollment:** 34 (ACTUAL)
- **Last updated:** 2011-02-24

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01302951

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01302951, "Penetration of Moxifloxacin Into Liver Tissue of Patients Undergoing Liver Resection.". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT01302951. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*